GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Profound Medical Corp (TSX:PRN) » Definitions » YoY EPS Growth

Profound Medical (TSX:PRN) YoY EPS Growth : 49.38% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Profound Medical YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Profound Medical's YoY EPS Growth for the quarter that ended in Dec. 2024 was 49.38%.

Profound Medical's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was C$-0.29.


Profound Medical YoY EPS Growth Historical Data

The historical data trend for Profound Medical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Profound Medical YoY EPS Growth Chart

Profound Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.25 -19.93 2.34 4.11 11.23

Profound Medical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.92 19.25 12.33 -46.31 49.38

Profound Medical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Profound Medical's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-1.596--1.798)/ | -1.798 |
=11.23 %

Profound Medical's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(-0.285--0.563)/ | -0.563 |
=49.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Profound Medical YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Profound Medical's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Profound Medical Business Description

Traded in Other Exchanges
Address
2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Executives
Dr. Arun Menawat Director, Senior Officer
Thomas Michael Tamberrino Senior Officer
Rashed Osman Dewan Senior Officer
Abbey Klair Goodman Senior Officer
Brian Ellacott Director
Murielle Lortie Director
Arthur Lee Rosenthal Director
Aaron Davidson Senior Officer
Guruprit Kour Singh Senior Officer
Ian Heynen Senior Officer

Profound Medical Headlines